MVA-B: The HIV vaccine is full of new prospects

Researchers from the Spanish Advanced Research Council, called CSIC, have brought good news to HIV-infected patients that they have completed phase 1 of the vaccine production process. -xin HIV. The vaccine called MVA-B uses the human immune system to fight HIV. MVA-B has proven to be as powerful as other vaccines being tested and even more powerful than them. 90% of volunteers who use MVA-B have shown good signs of the ability to control the development of this century's virus.

>>>Discover how to disable HIV virus

In 2008, it was clinically tested MVA-B vaccine in mice and monkeys and found that it was very effective against SIV, a virus that weakens the monkey's immune system. And now to test its protection against HIV, scientists have officially tested this vaccine on 30 healthy healthy volunteers, of whom 24 are being used. Real MVA-B and the remaining 6 people were given placebo. The trial period lasts 48 weeks.

HIV virus

To create MVA-B vaccine , four HIV genes have been implanted into another vaccine for smallpox MVA. The immune system of volunteers after being vaccinated with MVA-B will have to respond to MVA and HIV genes will not be able to replicate themselves so this process is extremely safe for them. In addition, the clinical trial of this new vaccine in healthy people helps their immune systems detect and fight the components of the HIV virus. "It's like you give a picture of HIV to the immune system so that it can later identify HIV," said Mariano Esteban, CSIC's lead researcher.

"Our bodies contain a lot of lymphocytes, each of which is programmed to fight other pathogens. Therefore, training in these lymphocytes is essential for us to be able to resist. again, pathogens, such as HIV, a virus that you can't destroy it naturally. "

Dr. Mariano Esteban, head of MVA-B vaccine team at CSIC

The team's work also discusses the two most important lymphocytes, T lymphocytes and lymphocytes T. The MVA-B vaccine stimulates the production of B-cell lymphocytes, which have the function of producing antibodies against HIV attack on healthy cells. When testing the blood of patients in the 48th week, people found that the bodies of about 72.7% of people who tried the drug developed antibodies against HIV. However, what makes the MVA-B vaccine so effective is that it can "fight" long-term with viruses, not just a few times. To do this, our bodies need T lymphocytes, which are produced right from the first time the body is attacked and will remain in the body for many years. The function of T-lymphocytes is to stimulate the immune response of cells that are attacked by viruses, making it possible to detect and destroy the HIV virus. Blood tests at week 48 show that the body of 85% of patients still retains the "memory" of T-lymphocytes, which means their bodies still store information about the HIV virus.

"The MVA-B vaccine meets the requirements of an HIV vaccine , " said Mariano. Although it cannot remove HIV from the body, the patient's immune system can keep the virus under control, preventing it from continuing to infect other cells. According to CSIC, "If MVA-B overcomes stage 2 and 3 of the clinical trial and is put into production, in the future, people can consider HIV like acne."